Usrenty
Authorised
This medicine is authorised for use in the European Union
ustekinumab
Medicine
Human
Authorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Usrenty is a medicine used to treat:
- moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin). It is used in adults and children from the age of 6 years whose condition has not improved with, or who cannot use, other systemic (whole-body) psoriasis treatments, such as ciclosporin, methotrexate or PUVA (psoralen ultraviolet A). PUVA is a type of treatment where the patient receives a medicine called psoralen, before being exposed to ultraviolet light;
- active psoriatic arthritis (inflammation of the joints associated with psoriasis) in adults, when the condition has not improved enough with other treatments called disease-modifying anti-rheumatic drugs (DMARDs). Usrenty may be used alone or combined with methotrexate (a DMARD);
- moderately to severely active Crohn’s disease (a disease-causing inflammation of the gut) in adults whose condition has not improved enough with other treatments for Crohn’s disease or who cannot receive such treatments.
Usrenty contains the active substance ustekinumab and is a biological medicine. It is a ‘biosimilar medicine’; this means that Usrenty is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Usrenty is Stelara. For more information on biosimilar medicines, see here.
Usrenty can only be obtained with a prescription and should be given under the supervision of a doctor who has experience in diagnosing and treating the diseases that Usrenty is used for.
In plaque psoriasis and psoriatic arthritis, Usrenty is injected under the skin. The first injection is followed by another injection 4 weeks later. After that, one injection is given every 12 weeks.
In Crohn’s disease, Usrenty treatment is started as an infusion (drip) into a vein lasting at least 1 hour. Eight weeks after the first infusion, Usrenty is given as an injection under the skin. Patients then continue with Usrenty given as an injection under the skin every 8 or 12 weeks, depending on how well the treatment is working.
Patients or their caregivers may inject Usrenty once they have been trained, if their doctor thinks that this is appropriate.
For more information about using Usrenty, see the package leaflet or contact your doctor or pharmacist.
The active substance in Usrenty, ustekinumab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a specific target in the body. Ustekinumab attaches to 2 messenger molecules in the immune system called interleukin 12 and interleukin 23. Both are involved in inflammation and other processes that are important in psoriasis, psoriatic arthritis and Crohn’s disease. By blocking their activity, ustekinumab reduces the activity of the immune system and the symptoms of these diseases.
Laboratory studies comparing Usrenty with the reference medicine Stelara have shown that the active substance in Usrenty is highly similar to that in Stelara in terms of structure, purity and biological activity. Studies have also shown that giving Usrenty produces similar levels of the active substance in the body to those seen with Stelara.
In addition, a study involving 384 adults with moderate to severe plaque psoriasis showed that Usrenty was as effective as Stelara at improving symptoms of the disease. After 12 weeks of treatment, PASI scores (a measure of disease severity and area of skin affected) had improved by around 80% in people receiving Usrenty and around 81% in those receiving Stelara.
Because Usrenty is a biosimilar medicine, the studies on the effectiveness of ustekinumab carried out with Stelara do not all need to be repeated for Usrenty.
For the full list of side effects and restrictions with Usrenty, see the package leaflet.
The safety of Usrenty has been evaluated and, on the basis of all the studies carried out, the side effects of the medicine are considered to be comparable to those of the reference medicine Stelara.
The most common side effects with ustekinumab (which may affect more than 1 in 20 people) include headache and nasopharyngitis (inflammation of the nose and throat). The most serious side effect with ustekinumab (which may affect up to 1 in 1,000 people) is serious hypersensitivity (allergic) reactions including anaphylaxis (sudden, severe allergic reaction with breathing difficulty, swelling, lightheadedness, fast heartbeat, sweating and loss of consciousness).
Usrenty must not be used in patients who have an active infection that the doctor considers important.
The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Usrenty has a highly similar structure, purity and biological activity to Stelara and is distributed in the body in the same way. In addition, a study in adults with plaque psoriasis has shown that Usrenty and Stelara are equivalent in terms of safety and effectiveness in this condition.
All these data were considered sufficient to conclude that Usrenty will have the same effects as Stelara in its authorised uses. Therefore, the Agency’s view was that, as for Stelara, the benefits of Usrenty outweigh the identified risks and it can be authorised for use in the EU.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Usrenty have been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Usrenty are continuously monitored. Suspected side effects reported with Usrenty are carefully evaluated and any necessary action taken to protect patients.
Usrenty received a marketing authorisation valid throughout the EU on 17 September 2025.
Product information
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Usrenty
- Active substance
- ustekinumab
- International non-proprietary name (INN) or common name
- ustekinumab
- Therapeutic area (MeSH)
- Crohn Disease
- Anatomical therapeutic chemical (ATC) code
- L04AC05
Pharmacotherapeutic group
ImmunosuppressantsTherapeutic indication
Plaque psoriasis
Usrenty is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A).
Paediatric plaque psoriasis
Usrenty is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.
Psoriatic arthritis (PsA)
Usrenty, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.
Crohn’s Disease
Usrenty is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist.
News on Usrenty
This page was last updated on